Suven Life Sciences, a clinical-stage biopharma company developing novel therapies for central nervous system (CNS) disorders, will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026 in London this week.

The presentations will be led by new data and updates from the company's ongoing global Phase-3 clinical program evaluating Masupirdine for agitation associated with Alzheimer's dementia, alongside progress in the Phase-2 clinical development of Usmarapride. 

The conference also provides Suven with a global platform to showcase advances across its neuroscience pipeline.

A key highlight will be the latest findings from the global Phase-3 Masupirdine study, including demographic and clinical characteristics of enrolled patients, offering fresh insights into the study population and the trial's progress. 

Suven will also present non-clinical and clinical research spanning multiple CNS programs, reinforcing its focus on developing innovative treatments for neurological disorders.